Skip to contentB
Bioadaptives, Inc.
B
BDPTBioadaptives, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$7.20K$7.20Kderived+80.7% vs Q4 2022 Net Income-$268.30K-$268.30KderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bioadaptives, Inc. · CIK 1575142 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$2,699+162.0% Operating Incomederived-$61,784— Operating Cash Flowderived-$91,296N/M Margins · derivedGross margin37.5%+11.6 pt vs Q4 2022
Operating margin-858.0%
Net margin-3725.9%−3016.1 pt vs Q4 2022
ended Dec 31, 2023 · filed Apr 10, 2024 · 101 d after period end